Table 2

Evaluation of 56 patients with chronic polyneuropathy, according to part 2 of the guideline

Results of electrophysiological testsUniform demyelinating (n=2)Non-uniform demyelinating (n=5)Axonal
Pure sensory (n=6)Purely motor (n=0)Sensorimotor (n=43)
Clinical featuresConsistent with hereditary demyelinating neuropathy (n=2)Consistent with non-uniform demyelinating neuropathy (n=4)Pure sensory (n=6)Pure motor (n=2)
Pure sensory (n=19)
Sensorimotor (n=22)
Patients wrongly assigned to this groupn=0n=1n=3n=4
Patients with unnecessary investigationsn=1n=2n=3n=19
Patients with too few investigationsn=0n=0n=1n=16
Final diagnosisCMT-I (n=1)Sequelae of Guillain-Barré syndrome (n=2)Vitamin B12 deficiency (n=1)CIAP (n=32)
X linked CMT (n=1)Multiple myeloma (n=1)Paraneoplastic polyneuropathy (n=1)CMT-II (n=3)
Leprosy (n=1)Sarcoidosis (n=1)Hypothyroidism (n=2)
DADS2-150neuropathy (n=1)Idiopathic pure sensory neuropathy (n=3)Sequelae of critical illness polyneuropathy (n=2)
Vitamin B12 deficiency (n=1)
Paraneoplastic polyneuropathy (n=1)
Sclerodermia (n=1)
Burning feet by diltiazem (n=1)
  • 2-150 DADS=Distal acquired demyelinating symmetric.